Watermark
Go to Asia edition

Alizyme

  • 22 Apr 2005

Nomura is leading a £30.5m capital increase for Alizyme, which develops treatments for obesity and gastrointestinal complaints.

Shareholders will be offered 30.5m shares in the company, equal to about 21% of its share capital, on a four-for-19 basis at a subscription price of 100p, a ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial
Log in

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bond Comments

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 Citi 344,931.23 1345 8.09%
2 JPMorgan 341,263.25 1468 8.00%
3 Bank of America Merrill Lynch 306,817.51 1057 7.19%
4 Barclays 256,761.63 967 6.02%
5 Goldman Sachs 227,538.09 771 5.33%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 BNP Paribas 47,043.60 195 6.55%
2 JPMorgan 46,108.71 102 6.42%
3 UniCredit 39,106.98 168 5.45%
4 Credit Agricole CIB 36,670.04 182 5.11%
5 SG Corporate & Investment Banking 35,773.91 138 4.98%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 JPMorgan 14,088.48 62 8.96%
2 Goldman Sachs 13,469.15 66 8.57%
3 Citi 9,948.21 58 6.33%
4 Morgan Stanley 8,572.10 54 5.45%
5 UBS 8,391.04 36 5.34%